Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$1.18 USD
-0.01 (-0.84%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $1.18 0.00 (0.00%) 6:28 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
HOWL 1.18 -0.01(-0.84%)
Will HOWL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOWL
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Pacira (PCRX) Tops Q4 Earnings Estimates
Other News for HOWL
Werewolf Therapeutics Adopts New Bylaws and Elects Directors
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy Rating Maintained | HOWL Stock News
Werewolf Therapeutics price target lowered to $9 from $10 at BofA
Werewolf Therapeutics price target lowered by $1 at BofA, here's why
Bank of America Securities Remains a Buy on Werewolf Therapeutics (HOWL)